-
Physicians Likely To Support Portola's Betrixaban
Tuesday, December 27, 2016 - 1:07pm | 250Read More...Morgan Stanley is bullish on Portola Pharmaceuticals Inc (NASDAQ: PTLA) following the FDA acceptance of betrixaban for priority review. With priority review, betrixaban will receive an accelerated assessment of six months with a PDUFA date of June 24, 2017. Betrixaban is an oral, once-daily Factor...
-
Sarepta's DMD Drug Should Have A Strong Launch, But Long-Term Prospects Uncertain
Thursday, October 27, 2016 - 7:44am | 252Read More...Sarepta Therapeutics Inc’s (NASDAQ: SRPT) first drug, Exondys 51 [eteplirsen] has been approved by the FDA for boys with Duchenne Muscular Dystrophy. Although approval for DMD therapy offers the company significant market opportunity, there are long-term uncertainties, Morgan Stanley...
-
Portola's AndexXa Still Approvable, But It Will Take Time
Friday, August 19, 2016 - 11:45am | 405Read More...Morgan Stanley’s Matthew Harrison believes regulatory updates regarding AndexXa and betrixaban were key drivers for Portola Pharmaceuticals Inc (NASDAQ: PTLA), which could offer clarity regarding approval timelines and restore investor confidence. Harrison maintains an Overweight rating on...
-
Morgan Stanley Adjusts Their View Of Biogen After Spinoff
Wednesday, August 17, 2016 - 9:17am | 303Read More...Biogen Inc (NASDAQ: BIIB) published a Form 10 for its hemophilia spin-off, Bioverativ. Morgan Stanley’s Matthew Harrison maintained an Overweight rating on the company, while reducing the price target from $385 to $368. The analyst revised the Biogen model to remove Hemophilia estimates...
-
Infinity Pharma At Risk Of AbbVie 'Walking Away'
Wednesday, June 15, 2016 - 8:08am | 320Read More...Infinity Pharmaceuticals Inc. (NASDAQ: INFI) released the initial data for Duvelisib on June 15, which were below expectations. Morgan Stanley’s Matthew Harrison downgraded the rating on the company from Overweight to Equal Weight, while lowering the price target from $11 to $1. Harrison...
-
These Analysts Like Syndax's Breast Cancer Drug
Monday, March 28, 2016 - 8:39am | 498Read More...Morgan Stanley’s Matthew Harrison initiated coverage of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with an Overweight rating and price target of $22, while Citi’s Joel Beatty also initiated coverage of the company with a Buy rating and price target of $24. Major Value Driver Both...
-
Morgan Stanley: Buy BeiGene's Global Upside
Monday, February 29, 2016 - 11:47am | 226Read More...Morgan Stanley’s Matthew Harrison initiated coverage of Beigene Ltd (ADR) (NASDAQ: BGNE) with an Overweight rating and a price target of $39, saying that China opportunity offers valuation support at around $25, while I/O combos offer upside in the global market. “BeiGene is...
-
Amgen Shares Move Higher Following Morgan Stanley Upgrade To Overweight
Tuesday, December 15, 2015 - 8:53am | 344Read More...Amgen, Inc. (NASDAQ: AMGN) shares climbed 2 percent on December 14, while remaining below their 52-week high of $181.81. Morgan Stanley’s Matthew Harrison upgraded the rating on the company from Equal-weight to Overweight, while raising the price target from $160 to $193. Amgen...
-
Bluebuird Bio Crashes Nearly 30%: What's Next?
Monday, December 7, 2015 - 11:53am | 1162Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) plunged nearly 30 percent Monday morning. Bluebird reported mixed results from its ongoing studies at an industry conference. Matthew Harrison of Morgan Stanley acknowledged he "took a swing and missed," but other top Wall Street pros...
-
Morgan Stanley Cuts bluebird bio, Slashes Price Target From $143 To $69
Monday, December 7, 2015 - 10:08am | 271Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) have gained 14 percent in the last one month, after having declined for most of the year. Morgan Stanley’s Matthew Harrison downgraded the rating on the company from Overweight to Equal-weight, while reducing the price target from $143 to $69...
-
Wall Street Defends AbbVie, Says Reaction Is Overdone
Friday, October 23, 2015 - 9:07am | 507Read More...Shares of AbbVie Inc (NYSE: ABBV) plunged more than 10 percent on Thursday, hitting a new 52-week low of $45.45. The FDA requested that the company update its HCV treatment Viekira's label to reflect several cases of liver injury. Matthew Harrison of Morgan Stanley and Chris Schott of...
-
Chimerix Downgraded At Morgan Stanley, More Upside May Be Elsewhere Firm Warns
Monday, October 5, 2015 - 8:37am | 340Read More...Chimerix Inc (NASDAQ: CMRX) shares are up 9 percent year-to-date, despite having lost 16 percent since September 8. Morgan Stanley’s Matthew Harrison downgraded the rating on the company from Overweight to Equal-weight, while reducing the price target from $56 to $50. While key data...
-
Regeneron Downgraded At Morgan Stanley; Better Biotech Peer Plays Elsewhere
Friday, October 2, 2015 - 10:24am | 339Read More...Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have declined 11.33 percent in the last month, touching lows of $441.765 on September 28. Morgan Stanley’s Matthew Harrison has downgraded the rating on the company from Overweight to Equal-weight, with a price target of $593...
-
Morgan Stanley On Big Biotech: Upgrades, Pfizer, Vertex, Alexion, Cuts Gilead, Valeant
Friday, October 2, 2015 - 8:26am | 802Read More...Shares in healthcare broadly and biotech specifically have been under pressure over the past one month. Most big biotech stocks are down since September 2. Morgan Stanley analysts have commented on the cash position and pipelines of big biotech companies, against the backdrop of growing...
-
Morgan Stanley Still Likes Biogen After Bleak Earnings
Monday, July 27, 2015 - 12:52pm | 317Read More...In a report published Monday, Morgan Stanley analyst Matthew Harrison maintained an Overweight rating on Biogen Inc (NASDAQ: BIIB), lowering his price target from $520 to $426. The stock was trading up more than 2 percent on Monday, hovering around $306. Sticking To His Guns Biogen...
